FDA pulls approval for avastin in breast cancer.
نویسنده
چکیده
The FDA has revoked approval of the breast cancer indication for bevacizumab (Avastin; Genetech), saying that studies have not shown enough of a benefit to outweigh the drug's serious and potentially life-threatening side effects.
منابع مشابه
Avastin hearing leads to more uncertainty over drug's future.
I n what could evolve into a major challenge to the U.S. Food and Drug Administration ’ s plans to require improvement in overall survival when confirming the benefit of accelerated-approval cancer-drugs, Genentech plans to conduct a new trial of bevacizumab that will use progression-free survival (PFS) in metastatic breast cancer patients as its primary endpoint, company officials said. The an...
متن کاملVascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression.
The E-cadherin transcriptional repressor Snail is a prognostic marker for metastatic breast carcinoma, as well as a critical determinant of tumor growth and recurrence. We define a non-angiogenic, autocrine function for the vascular endothelial growth factor-A (VEGF-A) in regulating Snail expression in breast tumor cells. The transfection of well-differentiated breast tumor cells with VEGF-A in...
متن کاملThe horizon of antiangiogenic therapy for colorectal cancer.
Vascular endothelial growth factor (VEGF) plays a crucial role in the growth and metastatic spread of cancer. Bevacizumab (Avastin) is the first commercially available VEGF inhibitor, earning U.S. Food and Drug Administration (FDA) approval in February 2004. In combination with fluorouracil (5-FU)-based chemotherapy, this agent significantly prolongs overall and progression-free survival of pat...
متن کاملFirst FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
On September 30, 2013, the FDA granted accelerated approval to pertuzumab (Perjecta; Genentech, Inc.) for use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. Th...
متن کاملAt loose ends: telomere theories of aging and cancer begin to converge.
from the German Breast Group (GBG44) randomly assigned 1,948 patients to receive neoadjuvant epirubicin and cyclophospha-mide followed by docetaxel with or without Avastin. In the Avastin group, PCR was 18.4%, compared with 14.9% in the non-Avastin arm. The other study, dubbed NSABP B-40, randomly assigned 1,206 patients to receive neoadjuvant docetaxel-based chemo-therapy with or without Avast...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cancer discovery
دوره 1 7 شماره
صفحات -
تاریخ انتشار 2011